Table 2

Univariable mediation analysis of risk of CV death with empagliflozin versus placebo: time-dependent covariate analysis adjusting for the change from baseline in each variable

HR for CV death with empagliflozin vs. placebo (95% CI)Percentage mediation
Unadjusted0.615 (0.491, 0.770)
Adjusted for
 HbA1c0.624 (0.496, 0.785)3.0
 FPG0.665 (0.529, 0.837)16.1
 SBP0.593 (0.473, 0.743)−7.5
 DBP0.614 (0.490, 0.769)−0.3
 Heart rate0.621 (0.495, 0.780)2.0
 LDL-C0.596 (0.475, 0.748)−6.5
 HDL-C0.636 (0.506, 0.799)6.9
 logTG0.604 (0.482, 0.758)−3.7
 FFAs0.586 (0.463, 0.741)−9.9
 logUACR0.649 (0.518, 0.815)11.1
 eGFR (MDRD)0.631 (0.504, 0.790)5.3
 eGFR (CKD-EPI)0.632 (0.505, 0.791)5.6
 Weight0.579 (0.461, 0.727)−12.4
 BMI0.578 (0.460, 0.726)−12.8
 WC0.598 (0.477, 0.750)−5.8
 Hematocrit0.791 (0.626, 1.000)51.8
 Hemoglobin0.780 (0.619, 0.983)48.9
 Albumin0.696 (0.555, 0.873)25.5
 Uric acid0.693 (0.553, 0.869)24.6
  • Cox proportional hazards regression analysis in patients treated with one or more doses of study drug. FFA, free fatty acid; HDL-C, HDL cholesterol; LDL-C, LDL cholesterol; TG, triglyceride; WC, waist circumference.